Navigation Links
Phase III Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Thera
Date:1/17/2012

WAYNE, N.J., Jan. 17, 2012 /PRNewswire/ -- Bayer HealthCare today announced latest data on its investigational compound regorafenib (BAY 73-4506) from the Phase III CORRECT (Colorectal cancer treated with regorafenib or placebo after failure of standard therapy) trial. The study met its primary endpoint, showing statistically significant improvement in overall survival (OS) by 29% (HR=0.77, p=0.0052, median OS: 6.4 months vs. 5.0 months for the placebo group) in patients with metastatic colorectal cancer (mCRC) whose disease had progressed after approved standard therapies.(1) This late-breaking abstract, with these updated data, will be presented by Axel Grothey, MD, Professor of Oncology, Mayo Clinic and co-principal investigator of the CORRECT study, in an oral abstract session (LBA No. 385, January 21, 2012 from 2:30 p.m. - 4:00 p.m. PT, Level 3 Ballroom, Moscone Center West) at the 2012 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI), in San Francisco, CA.

Additionally, findings from the secondary endpoints of the CORRECT study showed statistically significant improvement in progression-free survival (PFS) (HR=0.49, p<0.000001, median PFS: 1.9 months vs. 1.7 months) and an improvement in disease control rate (44.8% vs. 15.3%) in patients treated with regorafenib compared to those treated with placebo. The difference in objective response rate between the two arms (1.0% vs. 0.4%) did not reach statistical significance.(1)

The most common drug-related, treatment-emergent adverse events included fatigue (47.4% vs. 28.1%), hand-foot skin reaction (46.6% vs. 7.5%), diarrhea (33.8% vs. 8.3%), anorexia (30.4% vs. 15.4%), hypertension (27.8% vs. 5.9%), oral mucositis (27.2% vs. 3.6%) and rash/desquamation (26.0% vs. 4.0%) for patients receiving regorafenib as compared to placebo.(1)

Per the recommendation from an independent Data Monitoring Committee, the
'/>"/>

SOURCE Bayer HealthCare
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... Columbia and MENLO PARK, ... DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" ... developing and commercializing proven cancer therapies in new ... from its Phase I/II clinical trial of  VAL-083 ... the most common and deadly form of human ...
(Date:6/1/2015)... LONDON , June 1, 2015 ... carcinoma segment will drive growth , says   ... Cell Lung Cancer (NSCLC) treatment market will be driven primarily ... and squamous cell treatment settings, which either replace or combine ... GBI Research - Non-Small Cell Lung Cancer Market to ...
(Date:6/1/2015)... DUBLIN , May 29, 2015 ... the addition of the "Global Power Wheelchair ... The Global Power Wheelchair Industry Report ... the current state of the power wheelchair industry. ... of the industry including definitions, classifications, applications and ...
Breaking Medicine Technology:DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 2DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 3DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 4DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 5DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 6DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 7DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 8New Therapies to Enhance Increasingly Competitive Non-Small Cell Lung Cancer Treatment Market 2New Therapies to Enhance Increasingly Competitive Non-Small Cell Lung Cancer Treatment Market 3Global Power Wheelchair Industry Trends 2015-2020 2
... 2011 Alere Inc. (NYSE: ALR ), ... health at home through the merger of rapid diagnostics and health ... 31, 2010. Financial results for the fourth quarter ... the fourth quarter of 2010, compared to $546.2 million for the ...
... 2011 Cepheid (Nasdaq: CPHD ) today ... following investor conferences, and invited investors to participate via ... 1, 2011 at 8.30 a.m. Eastern TimeRBC Capital Markets, ... 11.00 a.m. Eastern TimeTo access the live webcasts for ...
Cached Medicine Technology:Alere Inc. Announces Fourth Quarter 2010 Results 2Alere Inc. Announces Fourth Quarter 2010 Results 3Alere Inc. Announces Fourth Quarter 2010 Results 4Alere Inc. Announces Fourth Quarter 2010 Results 5Alere Inc. Announces Fourth Quarter 2010 Results 6Alere Inc. Announces Fourth Quarter 2010 Results 7Alere Inc. Announces Fourth Quarter 2010 Results 8Alere Inc. Announces Fourth Quarter 2010 Results 9Alere Inc. Announces Fourth Quarter 2010 Results 10Alere Inc. Announces Fourth Quarter 2010 Results 11Alere Inc. Announces Fourth Quarter 2010 Results 12Alere Inc. Announces Fourth Quarter 2010 Results 13Alere Inc. Announces Fourth Quarter 2010 Results 14Alere Inc. Announces Fourth Quarter 2010 Results 15Alere Inc. Announces Fourth Quarter 2010 Results 16Alere Inc. Announces Fourth Quarter 2010 Results 17Alere Inc. Announces Fourth Quarter 2010 Results 18Alere Inc. Announces Fourth Quarter 2010 Results 19Cepheid to Webcast Upcoming Financial Presentations 2
(Date:6/2/2015)... June 02, 2015 Date: Thursday, June ... City Council Chamber, 494 N. Broad Street, 4th floor, ... Hepatitis B Foundation will visit Philadelphia City ... for hepatitis B and hepatitis C in Philadelphia’s at-risk ... campaign they have created, Hep B United Philadelphia (HBUP), ...
(Date:6/2/2015)... Join us for a new event in Westwood, New ... Martin , who overcame her brain aneurysm during the summer ... raising awareness and funds for brain aneurysm research. , ... there will be one less case of someone suffering from ... join the 1st Anniversary Awareness Walk in Honor of ...
(Date:6/2/2015)... Diego, CA (PRWEB) June 02, 2015 “We ... from damaging ultraviolet (UV) sun rays”, states Marta Phillips, owner ... selection of men’s sun hats and sun accessories that work ... exposure are not immediately evident. Sometimes sun damage can take ... ears and neck are prime areas for skin cancer to ...
(Date:6/1/2015)... 2015 The National Association of ... as a 2015-2016 inductee into the NAPW VIP Professional ... this prestigious distinction for leadership in academics. With more ... NAPW is the nation’s leading networking organization exclusively for ... this important distinction,” said NAPW President Star Jones. “She ...
(Date:6/1/2015)... 2015 The National Association of ... as a 2015-2016 inductee into its VIP Woman of ... distinction for leadership in mental health. NAPW is the ... more than 700,000 members and over 200 operating Local ... important honor," said NAPW President Star Jones. "Her knowledge ...
Breaking Medicine News(10 mins):Health News:Hepatitis B Foundation to Urge Philadelphia Leaders to Make Viral Hepatitis Prevention a Local Priority 2Health News:New Awareness Raising Event in Westwood, NJ to Benefit Renowned Brain Aneurysm Foundation 2Health News:It is Time to Show Father Who Knows Best, Says SunGrubbies.com, a Leading Online Sun Protection Retailer 2Health News:National Association of Professional Women Inducts Marcia Ditmyer, Vice President of Academy for Academic Leadership, Into its VIP Professional Woman of the Year Circle 2Health News:NAPW Inducts Selma Tansey, Executive Director of Washington Communities Human Services, Into its VIP Professional Woman of the Year Circle 2
... Master of Ceremonies, INDIANAPOLIS, May 2 Over ... for the annual Talk*Walk*Run (5K or 2.3,mile) on Saturday, ... Fort Harrison,State Park at 6002 N Post Rd., Indianapolis, ... officiate as Master of,Ceremonies. In 1999, Rep. Bosma championed ...
... ... ON THE MARKET!, PHILADELPHIA, ... Water and has issued its OCIA,International Organic Certification. The new certificate, ... and will make,Ayala,s Herbal Water the first nationally available organically certified,enhanced ...
... Global Action Plan for the Prevention and Control of Pneumonia ... It highlights research on the many aspects that drive this ... that is a priority if Millennium Development Goal 4 to ... this attention on childhood pneumonia? It is the leading killer ...
... NEW ORLEANS, La., May 2 Thermage, Inc.,(Nasdaq: ... company, will be a first,time exhibitor at The ... and Gynecologists (ACOG) at booth #2609. The presence ... of aesthetics is,becoming a more common option among ...
... Tour to Offer Free Skin Cancer Screenings And Education about ... ... announces their,sponsorship and the official kick-off of The Skin Cancer Foundation,s ... skin cancer,screenings, conducted by local board-certified dermatologists, in a private,room inside ...
... 2 CNS Response, Inc.,(OTC Bulletin Board: CNSO) ... Officer, CNS Response, Dr. Henry Harbin, M.D., Board ... Medical Officer, Walden,Behavioral Care Inpatient Psychiatry and Eating ... personalized medicine and,its potential for treating patients with ...
Cached Medicine News:Health News:Hear Indiana Announces Talk*Walk*Run 2008 2Health News:Hear Indiana Announces Talk*Walk*Run 2008 3Health News:USDA Grants Organic Certification to Ayala's Herbal Water(TM) 2Health News:Prevention and control of childhood pneumonia: Bulletin of the World Health Organization 2Health News:Thermage, a Leading Aesthetic Medical Device Company, Announces First Time Exhibitor Status at ACOG Meeting 2Health News:Thermage, a Leading Aesthetic Medical Device Company, Announces First Time Exhibitor Status at ACOG Meeting 3Health News:AVEENO(R) Announces Sponsorship and Kick-Off of The Skin Cancer Foundation's 'Road to Healthy Skin Tour' Presented by AVEENO(R) and Rite Aid 2Health News:AVEENO(R) Announces Sponsorship and Kick-Off of The Skin Cancer Foundation's 'Road to Healthy Skin Tour' Presented by AVEENO(R) and Rite Aid 3Health News:CNS Response, Inc: rEEG(R) Research to be Presented at 38th National Council Conference 2Health News:CNS Response, Inc: rEEG(R) Research to be Presented at 38th National Council Conference 3
... ACL 8000 is an easy-to-use, automated system ... array of assays for managing hemostatic disordersincluding ... S. Also offers reflex and rerun testing ... it's backed by our high-quality service to ...
... System is designed to provide excellent capture ... carotid stenting interventions. The ACCUNET is a ... utilizes rapid exchange technology so that the ... catheter manipulations. It is available in both ...
Four disposable disc electrodes are pre-gelled and attached to wires in red, blue, black and green. 4mil carbon film, Ag/AgCl coated. Each package contains 20 individually sealed sets of four leads....
Lancet cut ultra sharp tip for low penetration resistance. Low noise and impedance level giving you a clear and reliable signal. Stainless steel needle, color coded attached lead wires. Needles sold ...
Medicine Products: